A new preference-based analysis for randomized trials can estimate treatment acceptability and effect in compliant patients.

A new preference-based analysis for randomized trials can estimate treatment acceptability and effect in compliant patients. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

A new preference-based analysis for randomized trials can estimate treatment acceptability and effect in compliant patients. Abstract Text:

S D Walter,Gordon Guyatt,Victor M Montori,R Cook,K Prasad,

BACKGROUND AND OBJECTIVES: Development of a new method of analysis to evaluate the acceptability of (or preferences for) the treatments in a randomized trial, and the benefit of treatment among compliers. MATERIALS AND METHODS: We characterize trial participants through the groups who would: accept either treatment if offered (compliers); refuse one treatment but accept the other if it is offered to them (two groups of preferers); or prefer one treatment and insist on it if it is not offered to them initially (two groups of insisters). RESULTS: We show that in our framework, one can always estimate the proportions of patients in these five preference groups. However, constraints are required to estimate the corresponding outcome rates, and thus estimate the treatment effect in the compliers. We propose two possible sets of constraints and illustrate them by numerical examples. CONCLUSIONS: The traditional intention-to-treat analysis avoids biases associated with the alternative per-protocol or as-treated approaches, but it provides imperfect information about the expected treatment effect among patients who are committed to taking the treatment. Many physicians and patients want to know the expected benefit if they adhere to the therapy. Our preference-based analysis provides an estimate of treatment benefit among such patients.

A new preference-based analysis for randomized trials can estimate treatment acceptability and effect in compliant patients. Publishing Authors By Initials

SD Walter,G Guyatt,VM Montori,R Cook,K Prasad,

For similar behavior and behavior mechanisms: behavior: health behavior: treatment refusal research abstracts see: behavior and behavior mechanisms: behavior: health behavior: treatment refusal research

PUBMED ID PMID:

MEDLINE DATE:

A new preference-based analysis for randomized trials can estimate treatment acceptability and effect in compliant patients. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Journal of clinical epidemiology

VOLUME: 59

Page Numbers: 685-96

Journal Abbreviation:

ISSN: 0895-4356

DAY: 27

MONTH: 03

YEAR: 2006

A new preference-based analysis for randomized trials can estimate treatment acceptability and effect in compliant patients. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8801383

A new preference-based analysis for randomized trials can estimate treatment acceptability and effect in compliant patients. Keywords Mesh Terms:

KEYWORDS: Treatment Refusal

MESH TERMS: therapy

Chemical & Substance for Abstract: A new preference-based analysis for randomized trials can estimate treatment acceptability and effect in compliant patients. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for A new preference-based analysis for randomized trials can estimate treatment acceptability and effect in compliant patients.

AFFILIATION: Department of Clinical Epidemiology and Biostatistics, McMaster University, HSC-2C16, 1200 Main St West, Hamilton, Ontario L8N 3Z5, Canada. walter@mcmaster.ca

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Clin Epidemiol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

A new preference-based analysis for randomized trials can estimate treatment acceptability and effect in compliant patients Related Publications

• A Theoretical Math Model for Projecting AIS3+ Thoracic Injury for Belted Occupants in Frontal Impact.
• A new mutation in exon 3 of the SCL39A4 gene in a Tunisian family with severe acrodermatitis enteropathica.
• A new preference-based analysis for randomized trials can estimate treatment acceptability and effect in compliant patients.
• A simple and efficient method for the purification of seminal plasmin, an antimicrobial protein from bovine seminal plasma.
• Alpha tocopheryl succinate inhibits melanocyte-stimulating hormone (MSH)-sensitive adenylate cyclase activity in melanoma cells.
• Alpha tocopheryl succinate, retinoic acid and polar carotenoids enhanced the growth-inhibitory effect of a cholesterol-lowering drug on immortalized and transformed nerve cells in culture.
• Biomechanical Analysis of Human Abdominal Impact Responses and Injuries through Finite Element Simulations of a Full Human Body Model.
• Combined effect of adenosine 3',5'-cyclic monophosphate stimulating agents, vitamin E succinate, and heat on the survival of murine B-16 melanoma cells in culture.
• Cryoelectron microscopy structures of rotavirus NSP2-NSP5 and NSP2-RNA complexes: implications for genome replication.
• D-alpha-tocopheryl succinate (vitamin E) enhances radiation-induced chromosomal damage levels in human cancer cells, but reduces it in normal cells.
• Effect of alpha tocopheryl succinate on adenylate cyclase activity in murine neuroblastoma cells in culture.
• Effect of alpha tocopheryl succinate on cyclic AMP-dependent protein kinase activity in murine B-16 melanoma cells in culture.
• Effect of hyperthermia in combination with vitamin E and cyclic AMP on neuroblastoma cells in culture.
• Effects of dl-alpha-tocopheryl succinate in combination with sodium butyrate and cAMP stimulating agent on neuroblastoma cells in culture.
• Evaluation of intrarenal oxygenation in mice by BOLD MRI on a 3.0T human whole-body scanner.
• Improved neck injury risk curves for tension and extension moment measurements of crash dummies.
• Induction of autolysis in starved Escherichia coli cells by seminalplasmin, an antimicrobial protein from bovine seminal plasma.
• Induction of differentiated phenotypes in melanoma cells by a combination of an adenosine 3',5'-cyclic monophosphate stimulating agent and D-alpha tocopheryl succinate.
• Innovations in integrative healthcare education: the AMSA CAM education projects and the University of New Mexico Integrative Medicine Program.
• New method for delivering a hydrophobic drug for photodynamic therapy using pure nanocrystal form of the drug.
• Organically modified silica nanoparticles co-encapsulating photosensitizing drug and aggregation-enhanced two-photon absorbing fluorescent dye aggregates for two-photon photodynamic therapy.
• Quantum rod bioconjugates as targeted probes for confocal and two-photon fluorescence imaging of cancer cells.
• Rationale for using high-dose multiple dietary antioxidants as an adjunct to radiation therapy and chemotherapy.
• Regulation of the Expression of Tropomyosins and Actin Cytoskeleton by ras Transformation.
• Seminalplasmin, an antimicrobial protein from bovine seminal plasma, inhibits peptidoglycan synthesis in Escherichia coli.
• Study on the specificity of alpha-tocopheryl (vitamin E) acid succinate effects on melanoma, glioma and neuroblastoma cells in culture.
• The active site residue Valine 867 in human telomerase reverse transcriptase influences nucleotide incorporation and fidelity.
• Vitamin E (d-alpha-tocopheryl succinate) decreases mitotic accumulation in gamma-irradiated human tumor, but not in normal, cells.
• Zinc: mechanisms of host defense.
• dl-alpha-Tocopheryl succinate enhances the effect of gamma-irradiation on neuroblastoma cells in culture.